GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Rifampin

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Professional source

UCSF - rifampin: renal function and indication

Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal measure
Qualitative no-adjustment guidance.

Dosing / renal protocol and limits

No routine renal dose reduction is listed, including hemodialysis. Adult non-CNS mycobacterial infection: 600 mg IV or orally daily. Prosthetic-device infection: 300 mg every 12 hours or 600 mg daily. Endocarditis: 300 mg every 8 hours. Choose an indication-specific combination regimen and review major drug interactions; these entries do not authorize rifampin monotherapy.

Source revision: Revision date not stated in the reviewed page. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://idmp.ucsf.edu/content/rifampin

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Professional guidance

UCSF - rifampin: renal function and indication

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: Qualitative no-adjustment guidance.
Retrieved: 2026-09-05

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/rifampin/

Usual Dosing (Adults and children)

IV and oral doses are the same. Tuberculosis: adults, 10 mg/kg once daily, maximum 600 mg/day; pediatric patients, 10-20 mg/kg, maximum 600 mg/day. Oral doses are taken with a full glass of water 1 hour before or 2 hours after food.

The original source discusses all forms of TB and an initial 2-month rifampin/isoniazid/pyrazinamide phase. It describes adding ethambutol or streptomycin unless isoniazid resistance is very unlikely, reconsidering when susceptibility results are available, and considering fewer than four drugs where community isoniazid resistance is below 4%. It then describes at least 4 months of rifampin/isoniazid continuation and longer therapy for persistent sputum/culture positivity, resistance or HIV. These historical treatment-selection comments are not a newly validated TB guideline.

Meningococcal carriage: adults, 600 mg twice daily for 2 days; children at least 1 month, 10 mg/kg every 12 hours for 2 days, maximum 600 mg/dose; under 1 month, 5 mg/kg every 12 hours for 2 days.

GRPH-rifampin-01 · Source section: Usual Dosing (Adults and children)Renal section finder

Renal Dosing

At doses no greater than 600 mg/day, half-life is unchanged in renal failure, so no adjustment is described. Half-life at 720 mg/day in renal failure was not established.

After one 900 mg oral dose, mean half-life was 3.6 hours in healthy adults, 5 hours at GFR 30-50 mL/min, 7.3 hours below 30 and 11 hours in anuria.

GRPH-rifampin-02 · Source section: Renal DosingRenal section finder

Hemodialysis

The source refers to the preceding renal comments without an additional schedule.

GRPH-rifampin-03 · Source section: HemodialysisRenal section finder
Separate professional-source layer

University and professional protocols

Professional

UCSF - rifampin: renal function and indication

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: Qualitative no-adjustment guidance.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

No routine renal dose reduction is listed, including hemodialysis. Adult non-CNS mycobacterial infection: 600 mg IV or orally daily. Prosthetic-device infection: 300 mg every 12 hours or 600 mg daily. Endocarditis: 300 mg every 8 hours. Choose an indication-specific combination regimen and review major drug interactions; these entries do not authorize rifampin monotherapy.

RDM30-031-rifampin-1 · Source locator: UCSF - rifampin: renal function and indication; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/rifampin
Retrieved
2026-09-05
Renal-function method
Qualitative no-adjustment guidance.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
39b27c14f9566d103734a1842d3d9d84544bf1161cb4453558bfa7ff9a6f0f4e

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 0 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/rifampin/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
94dd83bdde638e7e2399c839bc88527eb452bd5b5d7e83bb8dd2d3a7143c0947
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report